DiaMedica Therapeutics Inc. to Post Q3 2024 Earnings of ($0.13) Per Share, HC Wainwright Forecasts (NASDAQ:DMAC)

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) – Investment analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of DiaMedica Therapeutics in a report released on Monday, October 7th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at ($0.55) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at ($0.47) EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. During the same period in the prior year, the business posted ($0.16) EPS.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $6.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, August 16th.

DiaMedica Therapeutics Stock Performance

DMAC opened at $4.65 on Wednesday. DiaMedica Therapeutics has a 52-week low of $1.94 and a 52-week high of $4.95. The firm has a market cap of $198.75 million, a P/E ratio of -8.30 and a beta of 1.48. The business’s fifty day moving average is $3.94 and its 200-day moving average is $3.25.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Paragon Associates & Paragon Associates II Joint Venture raised its stake in DiaMedica Therapeutics by 6.4% during the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after acquiring an additional 30,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of DiaMedica Therapeutics by 26.3% during the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after purchasing an additional 211,351 shares during the last quarter. Finally, Magnolia Capital Advisors LLC acquired a new position in shares of DiaMedica Therapeutics in the second quarter valued at approximately $87,000. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.